Celularity, Verséa sign distribution agreement for Biovance and Biovance 3L Ocular
Under the exclusive US commercialisation agreement, Verséa Ophthalmics will distribute Celularity’s ophthalmic products for the treatment of ocular…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Jul 23
Under the exclusive US commercialisation agreement, Verséa Ophthalmics will distribute Celularity’s ophthalmic products for the treatment of ocular…
28 Jul 23
For the efficacy estimand, participants in both trials who started taking GIP receptor after an intensive lifestyle intervention…
28 Jul 23
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease and…
28 Jul 23
Exercise of Procurement Options of Approximately $113m for Oral TPOXX and Approximately $25m for IV TPOXX under Current…
27 Jul 23
The review of the safety data was triggered following reports of suicidal thoughts and self-injury in people using…
27 Jul 23
V940-001 trial is a randomised, double-blind, placebo- and active-comparator-controlled study with a goal to assess the safety and…
27 Jul 23
The TAK-994-1501 Phase 2 study assessed the safety and efficacy of the OX2R agonist in narcolepsy type 1…
27 Jul 23
MyoPax aims to repair the congenital muscle defect associated with EEC using its cutting-edge highly regenerative muscle stem…
27 Jul 23
Reduction in blood oxygen levels, largely attributed to blocked airways, emerges as a leading factor.
26 Jul 23
Designed for small-to-medium-sized laboratories, DxC 500 AU is intended to improve laboratory workflows and support critical clinical decisions…